Cathie Wood’s ARK Invest recently made some changes to its biotech holdings while selling off stock in Coinbase and Ginkgo Bioworks. The reshuffling of the portfolio comes as ARK continues to make strategic moves in the market.
In a recent report, ARK revealed that it had sold off its shares in Coinbase, the popular cryptocurrency exchange platform. This move may have come as a surprise to some, as Coinbase has been a hot topic in the investing world. However, ARK seems to have decided to move on from its investment in the company.
Additionally, ARK also sold off its shares in Ginkgo Bioworks, a synthetic biology company. This decision could be part of ARK’s strategy to reallocate its resources and focus on other opportunities in the biotech sector.
On the biotech front, ARK made some changes to its holdings by reshuffling its portfolio. While the details of these changes were not disclosed, it is clear that ARK is actively managing its biotech investments to stay ahead in the market.
Overall, these recent moves by ARK show that the investment firm is constantly evaluating its portfolio and making strategic decisions to ensure its continued success in the market. Investors will be watching closely to see how these changes play out in the coming months.